

Supplementary table 1. Univariable analysis of mortality

	Alive (387)	Death (130)	p-value
Epidemiological features, n (%)			
Age, mean $\pm$ SD	64.3 $\pm$ 13.2	79.4 $\pm$ 11.6	<0.001
Female	183 (47)	44 (34)	0.008
Arterial hypertension	163 (42)	96 (74)	<0.001
Diabetes	53 (14)	38 (29)	<0.001
Chronic kidney disease	19 (5)	18 (14)	0.001
Hypercholesterolemia	121 (31)	66 (51)	<0.001
Smoking	22 (6)	5 (4)	
COPD	22 (6)	19 (15)	0.001
Ischemic cardiac disease	23 (6)	18 (14)	0.004
Previous AF episodes	23 (6)	25 (19)	<0.001
Cardiomyopathy	3 (1)	7 (5)	0.003
Previous heart failure admission	2 (1)	5 (4)	0.013
LVEF	61.7 $\pm$ 7.7	61.2 $\pm$ 9.5	0.726
Chronic oral treatment, n (%)			
RAAS inhibitors	127 (33)	67 (52)	<0.001
Diuretics	68 (18)	44 (34)	<0.001
Calcium-antagonists	43 (11)	21 (16)	0.128
Beta-blockers	52 (14)	41 (32)	<0.001
Anticoagulation	26 (7)	28 (22)	<0.001
Statins	112 (29)	49 (38)	0.344
Clinical findings, n (%)			

Days until admission, mean $\pm$ SD	8.7 $\pm$ 5.7	5.4 $\pm$ 3.6	<0.001
Length of admission (days), mean $\pm$ SD	10.4 $\pm$ 6.1	9.9 $\pm$ 8.7	0.545
Max temperature, mean $\pm$ SD	37.8 $\pm$ 1	37.7 $\pm$ 1	0.221
Cough	265 (69)	70 (54)	0.003
Rhinorrhea	10 (3)	1 (1)	0.471
Dyspnea	157 (41)	77 (59)	<0.001
Myalgias	87 (23)	12 (9)	0.001
Diarrhea	115 (30)	20 (15)	0.001
Odynophagia	32 (9)	1 (1)	0.004
Headache	21 (5)	3 (2)	0.144
Vomits	23 (6)	3 (2)	0.101
Anosmia	38 (10)	2 (2)	0.002
Treatment during hospitalization, n (%)			
Anticoagulation	246 (64)	80 (62)	0.679
Lopinavir/ritonavir	367 (97)	96 (84)	<0.001
Hydroxychloroquine	375 (99)	100 (87)	<0.001
Azithromycin	358 (95)	108 (94)	0.824
Ceftriaxone	244 (64)	87 (76)	0.024
Intravenous steroids	211 (56)	82 (71)	0.003
B1 Beta-Interferon	151 (40)	61 (53)	0.012
Tocilizumab	13 (3)	4 (4)	0.999
Laboratory results at admission, n (%)			
Leucocytes > 10.000/mm ³	41 (11)	48 (37)	<0.001

Leucocytes < 4.000/mm ³	53 (14)	11 (9)	0.111
Lymphocytes < 1.000/mm ³	167 (43)	84 (65)	<0.001
Hemoglobin <10 g/dL	16 (4)	16 (12)	0.001
Platelets <150.000/mm ³	64 (17)	37 (29)	0.003
D dimer > 500 ug/L	246 (67)	100 (83)	0.001
Creatinine > 1.5 mg/dL	23 (6)	50 (39)	<0.001
CRP > 10 mg/L	330 (87)	120 (95)	0.016
Procalcitonin > 0.5 ng/mL	15 (5)	41 (38)	<0.001
LDH > 250 U/L	213 (57)	100 (82)	<0.001
Adverse events, n (%)			
Acute myocardial infarction	1 (0.3)	0	0.999
Myocarditis	1 (0.3)	0	0.999
Heart failure	4 (2)	5 (5)	0.022
Ventricular arrhythmia	0	1 (1)	0.208
Atrial fibrillation	27 (7)	27 (21)	<0.001
Acute respiratory failure	108 (29)	109 (88)	<0.001
ICU admission	14 (4)	30 (25)	<0.001
Mechanical ventilation	13 (4)	27 (26)	<0.001
Major bleeding	6 (2)	10 (8)	0.999
Pulmonary embolism	9 (2)	2 (2)	0.739
Stroke	3 (1)	4 (3)	0.069

AF: atrial fibrillation. SD: standard deviation. COPD: Chronic obstructive pulmonary

disease. LVEF: left ventricle ejection fraction. RAAS: renin-angiotensin-aldosterone

system. CRP: C-reactive protein, LDH: lactate dehydrogenase. ICU: intensive care unit.